Skip to main content

Dr. Stacey M. Stein, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
22
In the NPI registry since
2007
Medicare patients seen, 2024
107

Licensed in Connecticut since 2010, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NJ license 25MA12494500
  • Hematology & Oncology Physician
    CT license 049046 (first issued 2010; inactive)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
107
Services billed
352
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes22563
Established patient office or other outpatient visit, 40-54 minutes2118
Telephone medical discussion with physician, 11-20 minutes1413
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes1212

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Sodium Chloride (0.9 % sodium chloride)
Other prescribers in New Haven, CT
48
Lenvima (lenvatinib mesylate)41
Humulin R (insulin regular, human)
Other prescribers in New Haven, CT
26
Imatinib Mesylate25
Ondansetron Odt (ondansetron)
Other prescribers in New Haven, CT
22

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 20 payments worth $14,472 in total to this clinician.

By company
Partner Therapeutics, Inc.$5,966
E.r. Squibb & Sons, L.l.c.$4,070
Boston Scientific Corporation$2,275
Guerbet LLC$2,161
By type
Consulting Fee$9,345
Travel and Lodging$2,691
Honoraria$2,000
Food and Beverage$436

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 6, 2025Partner Therapeutics, Inc.
Mar 6, 2025
Consulting Fee
Bizengri · Hematology/Oncology
$3,000
May 13, 2025E.r. Squibb & Sons, L.l.c.
May 13, 2025
Consulting Fee$2,590
May 7, 2025Boston Scientific Corporation
May 7, 2025
Consulting Fee
Clinical Trial Product · Clinical Trial Product_PI
$2,275
May 30, 2025Guerbet LLC
May 30, 2025
Honoraria
Lipiodol · HCC Contrast Agent
$2,000
Dec 8, 2025E.r. Squibb & Sons, L.l.c.
Dec 8, 2025
Consulting Fee$1,480
Feb 14, 2025Partner Therapeutics, Inc.
Feb 14, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$791
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$692
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$656
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind
$467
Mar 6, 2025Partner Therapeutics, Inc.
Mar 6, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$45.46
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 8, 2025E.r. Squibb & Sons, L.l.c.
Dec 8, 2025
Consulting Fee$1,480
May 30, 2025Guerbet LLC
May 30, 2025
Honoraria
Lipiodol · HCC Contrast Agent
$2,000
May 13, 2025E.r. Squibb & Sons, L.l.c.
May 13, 2025
Consulting Fee$2,590
May 7, 2025Boston Scientific Corporation
May 7, 2025
Consulting Fee
Clinical Trial Product · Clinical Trial Product_PI
$2,275
Mar 6, 2025Partner Therapeutics, Inc.
Mar 6, 2025
Consulting Fee
Bizengri · Hematology/Oncology
$3,000
Mar 6, 2025Partner Therapeutics, Inc.
Mar 6, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$45.46
Mar 6, 2025Partner Therapeutics, Inc.
Mar 6, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$34.77
Mar 6, 2025Partner Therapeutics, Inc.
Mar 6, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$5.07
Feb 14, 2025Partner Therapeutics, Inc.
Feb 14, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$791
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$692
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA
$656
Feb 13, 2025Partner Therapeutics, Inc.
Feb 13, 2025
Travel and Lodging
Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind
$467

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Connecticut →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $143,855 in research payments for these studies, mostly to the institutions running them.

  • Morpheus NeoAdj HCC
    Genentech, Inc.
  • A phase III,randomised,open label,sponsor blinded,multicentre study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first line treatment in patients with advanced hepatocellular carcinoma
    AstraZeneca Pharmaceuticals LP
  • PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC
    Genentech, Inc.
  • Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New Haven

Sources

NPI registry (CMS NPPES, November 2026; record last updated December 3, 2024), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1285824706. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.